593 related articles for article (PubMed ID: 29476996)
1. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
3. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
[TBL] [Abstract][Full Text] [Related]
4. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
6. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
Miglierini P; Bouchekoua M; Rousseau B; Hieu PD; Malhaire JP; Pradier O
Clin Neurol Neurosurg; 2012 Nov; 114(9):1222-5. PubMed ID: 22464950
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Pan E; Mitchell SB; Tsai JS
J Neurooncol; 2008 Jul; 88(3):353-7. PubMed ID: 18389176
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Salmaggi A; Milanesi I; Silvani A; Gaviani P; Marchetti M; Fariselli L; Solero CL; Maccagnano C; Casali C; Guzzetti S; Pollo B; Ciusani E; Dimeco F
J Neurosurg; 2013 Apr; 118(4):821-9. PubMed ID: 23350777
[TBL] [Abstract][Full Text] [Related]
11. Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice.
Roux A; Peeters S; Zanello M; Bou Nassif R; Abi Lahoud G; Dezamis E; Parraga E; Lechapt-Zalcmann E; Dhermain F; Dumont S; Louvel G; Chretien F; Sauvageon X; Devaux B; Oppenheim C; Pallud J
J Neurooncol; 2017 Oct; 135(1):83-92. PubMed ID: 28669011
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
13. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T
J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282
[TBL] [Abstract][Full Text] [Related]
15. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
McGirt MJ; Than KD; Weingart JD; Chaichana KL; Attenello FJ; Olivi A; Laterra J; Kleinberg LR; Grossman SA; Brem H; Quiñones-Hinojosa A
J Neurosurg; 2009 Mar; 110(3):583-8. PubMed ID: 19046047
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Barrié M; Couprie C; Dufour H; Figarella-Branger D; Muracciole X; Hoang-Xuan K; Braguer D; Martin PM; Peragut JC; Grisoli F; Chinot O
Ann Oncol; 2005 Jul; 16(7):1177-84. PubMed ID: 15857844
[TBL] [Abstract][Full Text] [Related]
17. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
Pallud J; Audureau E; Noel G; Corns R; Lechapt-Zalcman E; Duntze J; Pavlov V; Guyotat J; Hieu PD; Le Reste PJ; Faillot T; Litre CF; Desse N; Petit A; Emery E; Voirin J; Peltier J; Caire F; Vignes JR; Barat JL; Langlois O; Dezamis E; Parraga E; Zanello M; Nader E; Lefranc M; Bauchet L; Devaux B; Menei P; Metellus P;
Neuro Oncol; 2015 Dec; 17(12):1609-19. PubMed ID: 26185110
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Stummer W; van den Bent MJ; Westphal M
Acta Neurochir (Wien); 2011 Jun; 153(6):1211-8. PubMed ID: 21479583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
